A brain proteomic investigation of rapamycin effects in the Tsc1 +/− mouse model
Abstract Background Tuberous sclerosis complex (TSC) is a rare monogenic disorder characterized by benign tumors in multiple organs as well as a high prevalence of epilepsy, intellectual disability and autism. TSC is caused by inactivating mutations in the TSC1 or TSC2 genes. Heterozygocity induces...
Main Authors: | Hendrik Wesseling, Ype Elgersma, Sabine Bahn |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-08-01
|
Series: | Molecular Autism |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13229-017-0151-y |
Similar Items
-
Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Tsc-1-Suppressed Brain
by: Rebecca L. Cox, et al.
Published: (2018-11-01) -
Use of topical rapamycin in facial angiofibromas in Indian skin type
by: Vishalakshi Viswanath, et al.
Published: (2016-01-01) -
Topical rapamycin (sirolimus) for facial angiofibromas
by: Bhushan Madke
Published: (2013-01-01) -
Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex
by: Bo Zhang, et al.
Published: (2020-02-01) -
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
by: Michael Wong
Published: (2014-04-01)